For the roughly 30 million American adults who have been told their cholesterol is too high but cannot stomach a statin, the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Despite updated treatment guidelines, a prevalent gap ...

Please provide your email address to receive an email when new articles are posted on . CETP inhibition may help high-risk patients reach their LDL goals and reduce risk for atherosclerotic CVD events ...

NewAmsterdam Pharma's Obicetrapib is differentiated and improved from existing CETP therapies. The lipid-lowering therapy market with a CAGR of 7% over three years, represents significant blockbuster ...

February 5, 2009 (Rahway, New Jersey) — One of the first major clinical trials with Merck's new cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, has shown reassuring results, with ...

Phase III trial data support obicetrapib's lipid controlling effects in high-risk individuals without sufficient response to other lipid-lowering therapies. Obicetrapib is a highly selective CETP ...

New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to ...

Every 33 seconds, someone in the U.S. dies from cardiovascular disease. That statistic, part of 2021 data from the Centers for Disease Control and Prevention, represents a larger picture of heart ...

LONDON (Reuters) - The failure of Pfizer Inc's experimental cholesterol drug torcetrapib casts a shadow over the future of similar drugs from rival companies such as Roche Holding AG and Merck & Co ...

The last time I spoke about NewAmsterdam Pharma Company N.V. (NAMS) it was with respect to a Seeking Alpha article entitled "NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year ...

Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring ...

Statins do not help prevent Alzheimer’s disease, but another cholesterol-controlling drug just might. Obicetrapib blocks cholesteryl esters being transferred from the “good” high-density lipoproteins ...